Kazuomi Ueshima

Gunma Children's Medical Center — Japan

Medicine · Health Sciences

46h-index9.0kcitations395works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(156), Liver Disease Diagnosis and Treatment(86), Hepatitis C virus research(38), Hepatitis B Virus Studies(36), Cancer Mechanisms and Therapy(30)

Publications298 total

No Correlation Between Proteinuria and Renal Function in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: ARISE Study
Cancers·2025Open Access
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study
Hepatology Research·2025· 1 cited
Atezolizumab Plus Bevacizumab for <scp>TACE</scp> ‐Unsuitable Intermediate‐Stage <scp>HCC</scp> Beyond Up‐To‐7 Criteria: Final Analysis of <scp>REPLACEMENT</scp>
Liver International·2025· 2 citedOpen Access
Systemic Lupus Erythematosus Presenting as Symptoms of COVID-19-Associated Multisystem Inflammatory Syndrome in Children
The Kitakanto Medical Journal·2025Open Access
Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study
Liver Cancer·2025· 3 citedOpen Access
Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway
Clinical and Molecular Hepatology·2025· 7 citedOpen Access
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study
Journal of Gastroenterology·2025· 6 citedOpen Access
208P Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus bevacizumab (atezo+bev) for patients (pts) with Transcatheter arterial chemoembolization (TACE)–unsuitable intermediate-stage hepatocellular carcinoma (HCC) beyond the up-to-seven criteria
Annals of Oncology·2024Open Access
A Case of Fibrolamellar Hepatocellular Carcinoma in Which Tumor Control Was Achieved by Re‐Administering Atezolizumab and Bevacizumab
Cancer Reports·2024· 2 citedOpen Access
Analysis of tumor biomarkers in patients (pts) with advanced hepatocellular carcinoma (HCC) from a phase 1b study of E7386, a CREB-binding protein/β-catenin interaction inhibitor, in combination with lenvatinib.
Journal of Clinical Oncology·2024· 2 cited
Unresectable hepatocellular carcinoma after Fontan surgery: A case report
Kanzo·2023Open Access
171P Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Annals of Oncology·2023Open Access
205TiP IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Annals of Oncology·2023· 4 cited
Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations
Liver Cancer·2023· 16 citedOpen Access
Hepatocellular carcinoma with high MET gene amplification showed significant tumor shrinkage after cabozantinib treatment: A case report
Kanzo·2023Open Access
Low‐dose gemcitabine plus nab‐paclitaxel <i>versus</i> standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase <scp>II</scp> trial
JGH Open·2023· 1 citedOpen Access
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Liver Cancer·2023· 80 citedOpen Access
A phase 1b study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma.
Journal of Clinical Oncology·2023· 4 cited
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
Journal of Clinical Oncology·2023· 6 cited
Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma
Liver Cancer·2023· 13 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Masatoshi Kudo(51), Satoru Hagiwara(28), Yasunori Minami(23), Masahiro Takita(18), Naoshi Nishida(18), Tatsuo Inoue(17), Satoshi Kitai(16), Toshiharu Sakurai(14), Namiki Izumi(13), Norihisa Yada(13), Hobyung Chung(12), Masafumi Ikeda(11), Hirokazu Chishina(11), Hiroshi Ida(10), Hiroshi Aikata(9), Chikara Ogawa(9), Tomohiro Minami(8), Tomoko Aoki(8), Tadaaki Arizumi(8), Emi Ishikawa(8)